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Tests for detection of neurobehavioral changes in the offspring have been a regulatory requirement
in developmental toxicity testing of drugs for almost 20 years. Keeping their purpose of hazard
identification and risk assessment for humans in mind, investigators and agency reviewers have
become deeply ingrained with some stereotyped behaviors with respect to such relevant issues as
choice of animal species and data evaluation. Other problematic areas of study design and conduct,
selection of litter representatives for testing, what methods to combine in a testing battery, and
statistical treatment of results and their interpretation, will need more research and discussion in
the future. - Environ Health Perspect 104(Suppl 2):407-412 (1996)
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Introduction
The thalidomide tragedy in the early 1960s
brought about a worldwide realization that
drugs, pesticides, and other chemical sub-
stances have the potential to induce
damage in the unborn child. This was fol-
lowed by the introduction of new guide-
lines for preclinical testing requirements.
Naturally, interest focused mainly on struc-
tural abnormalities, and testing strategies
were devised that were expected to detect
and characterize prenatal insults leading to
gross morphological changes in the embryo
and fetus. Although experience has shown
that terata occur only rarely compared with
other end points ofdevelopmental toxicity,
such as effects on growth and viability, the
attitude that malformations are all impor-
tant still persists with many investigators
and regulatory agency reviewers.
As early as 1963, a fourth area of
concern, behavioral teratology, was intro-
duced in a review by Werboffand Gottlieb
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(1) on the postnatal effects of prenatal
X-irradiation and exposure to psychoactive
drugs. However, regulatory action was not
taken until 1975 when Great Britain and
Japan incorporated requirements for devel-
opmental neurotoxicity testing into their
respective guidelines for testing of medici-
nal products for reproductive toxicity. At
this time, the relevance to humans of the
potential ofchemicals to induce damage to
the central nervous system following prena-
tal exposure and exposure during child-
hood had become widely accepted based
on the data that were available for organic
mercury, lead, and alcohol. Although no
validated methods were available, it was
felt that early detection of a substance's
potential for developmental neurotoxicity
in animal experiments could prevent wide-
spread exposure of pregnant women and
thereby minimize or eliminate the risk for
the growing and developing child. It was
assumed that, for an unknown compound,
where no clues about the possible localiza-
tion ofa potential lesion existed, functional
tests might give greater sensitivity than
histopathological and biochemical meth-
ods. The underlying biological mechanisms
could then be elucidated by secondary
studies from the functional changes
observed in first-pass testing. Based on this
rationale, testing ofdrugs for end points of
developmental neurotoxicity commenced
in the mid-1970s, but it was not until the
early 1980s that behavioral testing batteries
became established as routine tests in the
pharmaceutical industry.
Since that time a large amount ofdata
on tests and test combinations for medicinal
products has accumulated in the archives of
regulatory agencies and pharmaceutical
companies, data that should be reexamined
critically with the aim ofidentifying meth-
ods that may be recommended.
Developmental Neurotoxicity
within the Framework of
Regulatory Studies
It was clear from the beginning that, for
therapeutic agents, neurobehavioral toxic-
ity testing would have to be incorporated
into existing study designs for the detec-
tion of any (adverse) effect on develop-
ment. These would have to be adapted to
allow the collection of information on
functional changes, in addition to the data
on viablity, growth, and gross structural
abnormalities of conceptus and offspring
(2). Regulatory studies for developmental
toxicity do not detect these different end
points equallywell. They can be considered
fairly sensitive for effects on viablity and
general growth parameters (body weight);
however, when the emphasis is placed on
rare events like malformations, a study size
of usually 10 to 20 pregnant animals per
group will always be insufficient in picking
up any but the strongest effects. Also, the
different variables constituting an embryo-
fetotoxic effect do not usually occurwith an
even distribution within and between lit-
ters of a dose group. Some litters may be
free of any relevant findings, others may
contain only one or a few affected fetuses
or pups, or, alternatively, the whole litter
may be abnormal. For nonfunctional end
points these distributions can be deter-
mined without great difficulty. But what
about effects on the functional integrity of
the central nervous system? How can we be
sure that the litter representatives chosen for
testing (in most studies by random meth-
ods) do indeed carry an alteration? Ifindi-
vidual distributions offunctional changes
are in any way similar to those existing for
other end points ofaberrant development,
with only a selection ofanimals from each
litter being tested, in routine studies we
should expect to miss quite a few substances
that affect CNS function.
Behavior may well be the most variable
parameter ofall the responses an organism
can make to a developmental toxicant.
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This is logical because uncompromised
animals will exhibit a wide range ofcom-
plex, adaptive behaviors without having to
compensate for substance-induced deficits,
and relatively small changes in the environ-
ment, e.g., handling ofanimals, maternal
influences, food restriction, and prior test
experience, have been shown to produce
alterations in normal behavior.
Characteristics of
DevelopmentalNeurotoxicity
Studies to detect developmental toxicity
differ in several important aspects from tests
in which toxicity is elicited in adults. The
main difference is the impossibility ofderiv-
ing untreated (control) as well as treatedval-
ues from the same animals. Comparisons to
determine whether there is a treatment
effect always will be made between groups
ofanimals that have different experiences
related to exposure and, even in inbred ani-
mals, different genetic compositions.
The developing nervous system may be
more sensitive to toxic effects than that of
the adult. Neurotoxic effects ofa chemical
may occur at lower doses than in adults,
different functions may be affected, and
substances that show no neurotoxic poten-
tial in adults may induce effects during
development. Therefore, we may suspect a
potential for developmental neurotoxicity
ifa compound induces neurotoxic changes
in adults, but we have to be aware ofthe
fact that compounds that do not affect the
adult nervous system may very well do so
in the developing organism. As testing is
performed to detect the unexpected, it will
be necessary to study end points for devel-
opmental neurotoxicity with all substances
for which exposure of the embryo, the
fetus, the newborn, the child, and thejuve-
nile cannot be excluded definitely. Unlike
malformations that can only be induced
during a narrow time window in organo-
genesis, functional changes can be expected
to occur during this differentiation phase
and, additionally, for as long a period as the
organ system needs to attain full functional
competence. For detection ofsuch effects,
animals will have to be exposed during
embryo-fetal development and postnatally
through puberty. Observation, however,
will have to continue for a longer time
period, ideally to old age, to make sure that
delayed manifestations are not overlooked.
None ofthe study designs currently recom-
mended by guidelines includes effects that
may become apparent only in aging ani-
mals, e.g., premature onset of senescence
or, with respect to CNS function, senility.
Animal Species
Rabbits, rats, and mice are the animal
species primarily used in routine develop-
mental toxicity testing; however, the
potential ofinducing neurobehavioral toxi-
city in the offspring is evaluated almost
exclusively in rats (Table 1). This is due to
the fact that regulatory agencies have
accepted data from rats in cases in which
this species proved to be an unsuitable ani-
mal model for the substance under study
when they should have encouraged the use
of another animal species. This practice
reveals astonishing insights into how great
an importance is attached to possible
effects with postnatal manifestations in
humans (including neurobehavioral find-
ings) during the process ofhazard identifi-
cation and risk assessment. At present, we
are making the world safer for rats. But
how secure can we feel about the detection
ofhazards for the developing nervous sys-
tem when this animal model is not even
reasonably close to humans? Even ifwe do
not yet know how changes in animal
behavior may translate to the situation in
humans, the least we can do is to use the
most appropriate animal model available to
us, i.e., that closest to humans with respect
to metabolism, pharmacokinetics, pharma-
codynamics, and physiology. If such a
species cannot be found or used, we should
consider conducting studies in more than
one animal species. This has been standard
procedure in the testing for structural
abnormalities and still is, despite intellectual
acknowledgement that one relevant species
is better than two or more less suitable ones.
Ifwe want to increase the predictability of
animal results for humans, it will be neces-
sary to develop methods for species other
Table 1. Use ofdifferentspecies and behavioral findings.
Not
Behavior evaluated Normal Affected
Fertility and general
reproduction studiesa
Rat 163 141 47
Mouse 4 2 1
Embryotoxicity studies
(Japanese guidelines)b
Rat 49 71 26
Mouse 5 1 4
Rabbit 5 1 0
Peri-postnatal studiesc
Rat 141 133 64
Mouse 5 3 2
Rabbit 3 0 0
"Exposure from before mating to the end of lactation.
bExposure during organogenesis. cExposure during
fetal development to the end of lactation.
than rats and to apply them in those cases
where the rat is not a relevant model.
Methods
Certainly, none ofthe commonly used lab-
oratory animal models can match the com-
plexity ofhuman behavior. For detection
studies, the animal model, the testing situ-
ation, and the available methods provide
the limiting factors and restrict investiga-
tors to analyzing basic neurological func-
tions and simple behaviors. Even given
these restrictions, there are more specific
functions than we could hope to incorpo-
rate and test in a single, comprehensive
study design. It may be considered advan-
tageous that the first guidelines required
testing ofspecific functions ofthe central
nervous system but, for lack ofexperience,
did not specifywhich tests were to be used.
This has resulted in a diversification of
methods and in a great variety of testing
batteries that are in regular use today. It
should be possible to identify sensitive and
reliable tests with predictive value for the
human situation. It is unlikely, however,
that a single ideal combination of testing
procedures could be defined-one that
would cover all aspects ofdevelopmental
neurotoxicity and that could be conducted
at reasonable costs.
Criteria for the selection of tests for a
testing battery have been described (3). For
detection ofany (adverse) effect, preference
is given to apical tests that require the inte-
grated function of several subsystems.
These mayoffer the best chance to discover
whether the substance poses a hazard to
development and function of the CNS
based on the assumption that a change in
any ofthe subsystems can lead to an alter-
ation in behavioral output. On the other
hand, with an increasing number ofsub-
systems involved, the animal will have
greater possibilities of compensating for
deficits in one subsystem. The choice of
methods should be aimed at having avail-
able a set ofapical tests that are neither too
complex nor too specific to incorporate
into routine developmental toxicity studies
and to supplement this battery with close
observation of the animals. If these give
indications for changes in behavioral end
points, other more sophisticated tests can
be used to clarify and characterize the results
obtained by the base set. Testing batteries
normally combine measurements ofgrowth
and physical development (2-6) with tests
for the development ofsensory functions,
reflexes, and body control, and protocols for
detecting changes in locomotor activity,
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learning/memory, and social/reproductive
behavior. As it will not be possible here to
describe methods in detail, the reader is
referred to several comprehensive reviews
on testing procedures and their respective
merits (3-8).
Reliability/Reproducbility
Regarding reliability oftesting procedures,
agency experience shows that most ofthe
tests incorporated into testing batteries and
retained by the investigators over the years
can be considered standardized andvalidated
with respect to intralaboratory reproducibil-
ity. Investigators do not tend to continue
using tests that will give vastly different
results from study to study, and it can be
seen from the submitted reports that compa-
rable values are found for control groups
over time. Interlaboratory reproducibility
has not been evaluated for all the tests used,
but the results from the comparison ofsome
of these methods in the study of the
National Center for Toxicological Research
(NCTR) have been encouraging (9,10).
Sensitity
Detection sensitivity of behavioral mea-
surements has been evaluated for the meth-
ods used in the NCTR Collaborative
Behavioral Teratology Study, and it can be
stated thatvariability ofthe measured para-
meters will allow detection ofeffects ifthey
are large enough (approximately 10-20%
change from control). However, it would
appear that neither this testing battery, nor
any other in current use, could be relied on
to detect a developmental neurotoxicant
among a series of unknown compounds.
One ofthe presumed positive control sub-
stances for the Collaborative Behavioral
Teratology Study, d-amphetamine, later
gave negative findings consistently within
and across the participating laboratories
(9). So either the assumption ofd.amphet-
amine being a strong developmental neuro-
toxicant was wrong or the test battery was
not suited to detect the deficits the sub-
stance did induce (11).
For a broader comparison ofmethods
not only for detection ofeffects but also for
characterisation, a European collaborative
study group was initiated. During this
study each participating group applied the
methods used in their laboratory to the
task ofdetecting neurobehavioral changes
induced by a known positive. The outcome
of this investigation shows that it is not
necessary to work with a standardized set
ofmethods to detect adverse effects on the
behavior ofoffspring (12,13).
Comprehensiveness
Selection ofa comprehensive testing battery
is a crucial point, especially as it will not
become apparent until much later whether
the aim has been achieved. Although no
consensus for recommending specific tests is
in sight, there seems to be some general
agreement on the functions that should be
tested, namely, sensory systems, reflexes,
neuromotor development, locomotion/activ-
ity, reactivity/habituation, learning/memory,
and social/reproductive behavior. To inte-
grate behavioral data into the context of
other manifestations ofdevelopmental toxi-
city, data on physical development ofthe
offspring have to be available. These com-
monly include data on body weights and
postnatal weight gain, viability, physical
landmark development and maturation. It
has also been recommended to maintain
records oforgan weights, especially brain,
functional observation battery results, neu-
ropathologic examinations (14), and brain
biochemistry (15,16).
Predictability
Little can be said about whether the tests in
current use predict that similar (or differ-
ent) effects on CNS development and
function would be elicited in humans.
They are able to identify known human
developmental neurotoxicants, but it can be
argued that this is due to selection bias and
to the fact that we already know what to
lookforwith these substances. Predictability
could be evaluated by using data on new
therapeutic agents, but lack ofhuman data
effectively prevents this.
ComputerizedProcduresvesus
Human Observe
For a novel, unknown compound, detec-
tion of an effect will depend to a large
extent on the observational skill and the
knowledge ofthe investigators, who can do
what a standardized test is unable to
accomplish; that is, they can pick up unex-
pected effects by observation and verify
them by specifically designed procedures.
Most tests yield not only variables that can
be measured exactly but also give rise to
findings for which measurement is difficult
or impossible and that will have to be
observed and described.
Asimple water maze, for example, which
is part ofmany routine testing batteries, will
be used to collect data on learning ability
and memory. The parameters recorded rou-
tinely are whether the animal is successful
within the time limit, the number oferrors
made, and the time needed to escape from
the maze. Experience shows that most (all?)
animals will learn the route that takes them
to the exit easily once they have managed to
discover (or have been shown) where it is
situated. Probably this is not a very sensitive
test for the detection ofsubtle differences in
learning/memory functions, as the perfor-
mance ofrats is quite variable even in con-
trol groups, and the demands on the central
nervous system ofthis simple task do not
seem to be high enough to bring out clear
effects on learning ability when brain dam-
age is slight. In addition, the way the test is
applied and evaluated, often only as a mea-
sure oflearning, does not make use of its
full potential. The first trial, in which the
naive animal has no due about the location
ofthe exit, more often than not is treated as
a training run, and, therefore, is not consid-
ered for further analysis of(learning) behav-
ior. In a study report, the reviewer will be
told how many animals failed to reach the
exit in time, but the reasons why they failed
to do so are never described. Ifthis were
done, we could gain insight into problem-
solving abilities and strategies that might be
more sensitive to chemical insults than sim-
ple learning tasks; this also may be more rel-
evant for extrapolation to humans and for
riskassessment.
Here human observers have definite
advantages over automated systems. They
are able to recognize behavioral changes in
the subjects that have not been anticipated
and are therefore not covered by the record-
ingprocedure ofthe program. On the other
hand, humans are at a severe disadvantage
when they are asked to carry out robotic
functions, such as observing large numbers
ofanimals in a specific test for hours and
recording behavioral parameters. Human
operators become bored or tired and their
attention wanders unless it is triggered by
something unusual. To design tests that can
be employed safely in the detection ofneu-
robehavioral toxicity, it is necessary to
understand these limitations and to use
both human observers and automated tests
for the purposes they can serve best-
humans to spot any uncommon and unpre-
dicted response and computers for counting
and recording tasks that can be anticipated
and programmed.
What Have We Learned from
Over 10 Years ofTesting
Therapeutic Agents?
In the overview that follows, we have fol-
lowed the interpretation ofthe investigators
who conducted the studies in categorizing
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findings as positive or negative. It must be Table 2. Fertility and general reproduction studies. Table 4. Peri-postnatal studies.
kept in mind, however, that the most com- Rat Rat
monly used methods of statistical analysis BeairNmlAfctd ehvoNral fetd
in these studies apply measures of central
BeairNmlAfctd ehvoNral fetd
tendency and that these are inappropriate Total studies 141 47 Total studies 133 64
to analyze values with a skewed distribu- No maternal toxicity 62 15 No maternal toxicity 50 19
tion that are generated by many behaviorAl Maternal toxicity 73 26 Maternal toxicity 73 36
test procedures. Strategies to improve Maternal death 6 5 Maternal death 10 9
valiity f deelop enta neuotoxCity Postimplantation loss normal 35 7 Postimplantation loss normal 44 12 validityof dvelopmental eurotoxicity Postimplantation loss increased 22 9 Postimplantation loss increased 30 14
testing should include improvement Of Pup mortality normal 86 25 Pup mortality normal 64 26
data exploration and analysis. Pup mortality increased 53 22 Pup mortality increased 69 38
Virtually all preclinical testing for Fetal weight normal 72 23 Pup weight normal 51 19
developmental neurotoxicity with new Fetal weight decreased 56 23 Pup weight decreased 79 45
medicinal substances has been carried out Pup weight normal 72 18 Pup weight increased 2 0
in rtsTabl1) Evn th Jaanes gude- Pup weight decreased 64 28 Pregnancy duration normal 102 47 in ratsTable 1) Even th Japanes guide- Pup weight increased 1 1 Pregnancy duration shortened 3 1
lines that required postnatal testing of off- Malformations normal 93 32 Pregnancy duration increased 26 14
spring in embryotoxicity studies, in which Malformations increased 7 2 Development normal 89 38
two species traditionally have been used, Skeletal variant negative 75 22 Development affected 37 22
have done so only for rodents but not for Skeletal variant positive 36 15
other species. Considering requirements Pregnancy duration normal 97 36
for species selection in current guidelines Pregnancy duration shortened 3 0 Table 5. Studies in rats with behavioral changes bydrug Pregnancy duration increased 34 11 idcto lse. for industrial chemicals and pesticides, the Development normal 107 25 idcto lse.
situation is similar in these areas and not Development affected 26 21 Drgcas FtityEbooxiyPe-sntl
likely to change in the near future.
Du ls etlt mrooiiyPr-otaa
Relevance of reproductive studies in rats, Analgesic! 3 2 3
when rodents are inappropriate models for Table 3. Embryotoxicity studies(Japanese guidelines). antiphlogistic (9) (6) (15) Antiallergic! 5 2 3
humans, is beginning to be addressed by Rat corticoid (17) (8) (11)
harmonized guidelines. These aim at detec- Behavior Normal Affected- Antibiotic! 10 6 13
tion ofreproductive toxicity for medicinal Toa .tde 1 2 antiviral (21) (21) (33)
products that require the use of a relevant Ttlsuis7 26 Antimycotic 2 0 2
animal model. These considerations also No maternal toxicity 21 4 (8) (2) (9)
apyfor developmental neurotoxicity. Maternal toxicity 46 18 Cardiovascular 15 4 13 apply onbhvoa Maternal death 4 4 (40) (18) (41)
Effects n behavoral paametersare not Postimplantation loss normal 32 10 Anticoagulant 1 0 0
uncommon in reproductive toxicity studies, Postimplantation loss increased 12 8 (4) (1) (4)
regardless ofwhether the period ofexposure Pup mortality normal 49 19 Anticonvulsant 0 1 3
occurs in early or late pregnancy or during Pup mortality increased 21 6 (3) (3) (3)
lactation. They occur in an order of mani Fetal weight normal 33 8 Psychoactive 1 3 4
tude similar to skelet.al variants or magcs ni Fetal weight decreased 34 16 (15) (5) (15)
postnatal viability anddevelopm~~~~~~~~~~~effetsNon Pupweight normal 24 7 Musclerelaxant!
postnataliability nd develoment. Not Pup weight decreased 18 10 spasmolytic (2) (2) (4)
surprisingly, behavioral alterations in off- Pup weight increased 2 0 Expectorant! 1 2 1
spring are associated with maternal toxicity, Malformations normal 58 20 broncholytic (8) (5) (3)
with decreased pup weight, and with effects Malformations increased 9 3 Hyperlipemic 0 0 1
on postnatal physical development-usually Skeletal variant negative 31 14 (3) (3) (5)
delays(Tables2-4). ~Skeletal variant positive 34 11 Gastrointestinal 2 0 1
If rug ar aalyed ccodig t thir Pregnancy duration normal 29 12 (10) (6) (9)
If drugsare anayzed acording o their Pregnancy duration shortened 2 0 Hormone!inhibitor 1 0 2
indication group, it becomes apparent that Pregnancy duration increased 12 7 (8) (5) (6)
positive findings on behavior are encoun- Development normal 52 17 Cytostatic 0 1 1
tered in very different drug classes (Table Developmentaffected 17 8 (2) (3) (3)
5) and not only with those compounds 'Data represent the number of positive studies, with the
that are known to be centrally acting. In 24 total number of studies shown in parentheses.
of all the substances tested, behavioral
changes were found either to be the only
adverse effects that could be detected at Almost all behavioral testing batteries learning and center latency in the open
any dose, or they occurred at the LOAEL contain one or more tests to measure activ- field test (Table 6).
together with other signs ofdevelopmental ity. From experiences with the testing ofnew Often effects are detected only in one
toxicity. Seven of these 24 compounds drugs, these seem to be very sensitive in pick- sex (Table 7). WhAether this is due to a true
were antibiotic drugs. Since the effects ing up effects at low doses, maybe overly so, sex-specific action of the compound can-
were not expected, this shows the necessity but for a detection study this would not be not be decided, as studies for secondary
ofconducting developmental neurotoxicity considered a disadvantage. Other tests and characterization are usually performed
tests for all substances to which the devel- parameters that showed significant changes only if malformations are encountered in
oping human will be exposed. at low doses are active and passive avoidance the routine studies, not for a suspected
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Table 6. Behavioral tests giving positive results in detection studies fortherapeutic agents.
Test system All Only at Below As LOAE
or parameter studies mattox mattox devtox
Activity(all)a 34 19 15 9
Hole board 3 2 1 -
Open field
Activity 14 10 4 3
Latency 7 1 6 5
Rearing 10 4 6 3
Grooming 2 1 1 1
Defecation 5 2 3 2
Avoidance learning 7 1 6 6
Water mazes 13 9 4 2
Rotarod 14 6 8 4
Swimming development 4 4 - -
Cliff avoidance 1 - 1 1
Negative geotaxis 4 3 1 -
Olfactory discrimination 1 1 - -
Homing 2 2 - -
Righting 16 9 7 1
Grasping 4 1 3 1
Placing 1 - 1 1
Abbreviations: mat tox, maternally toxic dose; LOAE, lowest observed adverse effect; dev tox, developmental
toxicity. "Includes open field and hole board locomotor activity.
effect on behavior. Unfortunately, with the
possible exception ofrearing behavior, the
available database is still not large enough
to identify specific functions or parameters
that are influenced preferentially in either
males or females.
Results
The relevance of the results within the
animal model has to be decided before
extrapolation to humans is attempted.
Magnitude ofthe effect, reversibility, and
possible relations to other effects, develop-
mental or maternal, will have to be consid-
ered. Changes that do not persist as the
animal gets older will probably bejudged to
have a different impact than permanent
effects, although with behavioral end points
the ability ofthe animal to compensate for
deficits has to be taken into account.
Risk Assessment and
Risk Management
Are behavioral results ofanimals exposed to
a substance during development predictive
ofsafety or hazard for developing humans?
Animal models are definitely affected by
the potent neurotoxicants that have been
found to induce brain damage and dys-
function in the human conceptus and chil-
dren, but these substances are too few in
number to allow generalization. Moreover,
substances presumed to be safe in humans
have not been evaluated to the same extent,
and no good evidence can be gained from
the testing ofnew compounds because data
on effects in humans will not be available
for manyyears to come.
The aim ofpreclinical testing is primary
prevention. Ifneurobehavioral changes are
encountered at a relevant dose in an animal
model exposed to a drug during develop-
ment, the regulatory agencywill not be in a
great hurry to find out what happens when
this drug is given to pregnant women. The
drug would be treated like a substance that
induces structural abnormalities in animals.
Ifno other problems prohibit granting ofa
license, the drug could be placed on the
market. However, use during pregnancy,
Table7. Frequency ofbehavioral effects in one sexonly.
Males and Only Only
Test system females males females
or parameter affected affected affected
Activity (all) 26 5 3
Hole board 3 2 -
Open field
Activity 11 1 2
Latency 5 1 1
Rearing 5 4 1
Grooming - 1 1
Defecation 4 - 1
Avoidance learning 3 2 2
Watermazes 7 2 4
Rotarod 12 2 -
Swimming development 4 -
Cliffavoidance 1 - -
Negative geotaxis 2 1 1
Olfactory discrimination - 1 -
Homing 2 - -
Righting 15 1 -
Grasping 4 - -
Placing 1 - -
during lactation, and in children would be
contra-indicated unless the drug has lifesav-
ing properties or another dear benefit that
would justify the perceived risk. Women of
child-bearing potential would be advised to
take contraceptive measures during and
after treatment (for drugs with a longer
half-life). For these reasons, we will not
learn-unless by accident-whether the
toxic potential, teratogenic or functional, is
relevant for humans. Inadvertent exposure
does occur, but given that behavioral
responses are more variable and differences
from normal may be more subtle rendering
them less conspicuous than morphological
effects, it is difficult to imagine how iso-
lated cases of behavioral abnormalities
could be noted and reported.
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